Daiichi Sankyo Company, Limited DSKYF
Set alert
17.26 USD +0.29 +1.71%
At close · Oct 30
18.70 Day range 18.70
13.85 52-week range 25.75
- YTD
- -19.72%
- 1 year
- -32.50%
- Open
- 18.70
- Prev close
- 16.97
- Mkt cap
- 31.41B
- Vol
- 5
- Avg vol
- 4.04K
- EPS
- 0.86
- P/E
- 20.07
More statistics
- Low
- 18.70
- High
- 18.70
- Earnings
- Nov 4, 2026
News
3 days ago businesswire.com
Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ending September 30, 2026. “Strong revenue growth continues in the second…
3 days ago businesswire.com
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union
MUNICH--(BUSINESS WIRE)--The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination…
-
6 days ago benzinga.com
Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1First EU…